MTFB.L Regulatory News (MTFB)

Motif Bio plc

("Motif Bio" or the "Company")

Amphion Innovations plc

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement this morning by Amphion Innovations plc ("Amphion"), that Amphion has pledged 14,906,145 ordinary shares of 1 pence each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion's loan facility.

Graham Lumsden, CEO of Motif Bio, commented: "We welcome Amphion's continued commitment as a shareholder in Motif Bio."

For further information please contact:

About Motif Bio (www.motifbio.com)

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.